CAR-T cell therapy in developing countries: how long should we wait?
Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatment...
Saved in:
| Main Authors: | Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/12/e009611.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pyogenic granuloma-like lesion in children: Should we wait?
by: Lai Kuan Chooi, et al.
Published: (2017-01-01) -
Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?
by: Isabella Fichtner, et al.
Published: (2024-12-01) -
Advanced heart failure with reduced ejection fraction at a young age: how long can we wait?
by: Arnold Péter Ráduly, et al.
Published: (2024-12-01) -
How should we think about the pollination crisis?
by: James Thomson
Published: (2025-04-01) -
How Much Should We Teach the Enigma Machine?
by: Jeffrey A. Livermore
Published: (2017-06-01)